Allozymes
Allozymes is a Singapore-based biotech that engineers enzymes for oligonucleotide therapeutic manufacturing and industrial biocatalysis using its proprietary ZymeLeap™ microfluidics and machine learning platform, selling off-the-shelf enzyme products and custom engineering services to pharmaceutical, chemical, and food companies.
- Company typePrivate
- Founded2019
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Allozymes does
Allozymes is a Singapore-based biotechnology company founded in 2019 that engineers enzymes for oligonucleotide therapeutic manufacturing and industrial biocatalysis. The company's core technology is the proprietary ZymeLeap™ platform, which integrates ultra-high-throughput microfluidic droplet screening (capable of testing 10+ million enzyme variants per day at 5–6 kHz), computational bioinformatics, and machine learning into a closed-loop Design-Build-Test-Learn workflow. Each screening droplet feeds an evolving enzyme knowledge database that powers ML-guided hit prioritization, focused library design, and iterative optimization of enzymes for activity, stability, specificity, and manufacturability. Allozymes complements the platform with integrated upstream and downstream capabilities spanning small-scale validation (1.5L, 14L fermenters), pilot-scale readiness (150L), cell lysis, chromatography, and QA/QC, enabling process-ready enzyme supply from screening to commercial scale-up.
The company operates a dual commercial model: off-the-shelf sales of an engineered enzyme portfolio (RNA Ligases, DNA Ligases, Glucose Dehydrogenases, Unspecific Peroxygenases, Transaminases, Amino Acid Dehydrogenases, Adenosine Deaminases, and Kinases) available up to API commercial production scale, paired with multi-year enzyme engineering service partnerships in which the ZymeLeap platform is embedded into customer development roadmaps. Customer segments span pharmaceutical and biotechnology companies (primary, focused on siRNA, ASO, and bioconjugate manufacturing), industrial chemicals, and food and nutrition. Allozymes is headquartered at 79 Science Park Drive in Singapore with a secondary office in Toulouse, France, and has raised over $22 million in total funding, most recently a $15 million Series A in May 2024 co-led by Seventure Partners and Xora Innovation. Named enterprise customers include Adisseo, Bonumose, and Harrison SPARC.
Allozymes firmographics
Firmographics- Name
- Allozymes
- Legal name
- ALLOYZMES PTE. LTD.
- Website
- https://allozymes.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Allozymes is a Singapore-based biotech that engineers enzymes for oligonucleotide therapeutic manufacturing and industrial biocatalysis using its proprietary ZymeLeap™ microfluidics and machine learning platform, selling off-the-shelf enzyme products and custom engineering services to pharmaceutical, chemical, and food companies.
- Ownership category
- akta.pro rank
Allozymes industry classification
Industry- Product category
- Enzyme Engineering and Biocatalysis
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
- akta.pro secondary industries
- Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids) (EUAAAIAL), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Enzymes & Processing Aids (Baking, Brewing, Dairy, Meat) (CRADAOAH)
Keywords
Where Allozymes is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices2 records
Markets served
Allozymes business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Enzyme Product Sales: Sale of off-the-shelf engineered enzymes including RNA ligases, DNA ligases, glucose dehydrogenases, unspecific peroxygenases, transaminases, amino acid dehydrogenases, adenosine deaminases, and kinases. Available up to API commercial production scale.
- Enzyme Engineering Services: Long-term collaborative partnerships where enzyme engineering is embedded into customer development roadmaps. Co-design and optimize enzymes using ZymeLeap platform from early route scouting to commercial scale-up.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Allozymes product offering
Product offeringCore offering
Allozymes engineers and supplies high-performance enzymes and enzyme engineering services using its proprietary ZymeLeap platform, which combines ultra-high-throughput microfluidics screening, computational design, and machine learning. The company sells an off-the-shelf portfolio of engineered enzymes (RNA ligases, DNA ligases, glucose dehydrogenases, unspecific peroxygenases, transaminases, amino acid dehydrogenases, adenosine deaminases, and kinases) and offers long-term collaborative enzyme engineering partnerships for pharmaceutical, biotech, industrial chemical, and food/nutrition customers.
Product overview
Allozymes offers a unified platform-plus-products architecture centered on the proprietary ZymeLeap™ platform, which integrates ultra-high-throughput microfluidics screening, computational design, and machine learning to engineer superior enzymes. The company provides an off-the-shelf portfolio of engineered enzymes for oligonucleotide manufacturing (RNA Ligases, DNA Ligases) and industrial biocatalysis (Glucose Dehydrogenases, Unspecific Peroxygenases, Transaminases, Amino Acid Dehydrogenases, Adenosine Deaminases, Kinases), complemented by enzyme engineering services for custom partnerships. The ZymeLeap platform serves as the core technology engine that drives enzyme discovery and optimization, while the enzyme products and services represent the commercial offerings built upon this platform.
Differentiator
Problem solved
Functional benefit
Brands
- ZymeLeap™: Proprietary enzyme engineering platform integrating ultra-high-throughput microfluidics screening, computational design, and machine learning for enzyme development.
Products and services
- RNA Ligases
Quantifiable outcome
- 10+ million enzyme variants screened per day using microfluidic droplet technology
- +2 more outcomes
Companies that use Allozymes
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Allozymes technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature6 records
Allozymes partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- AdisseocoreLong-term collaboration where Allozymes designed, synthesized, and screened millions of enzyme variants to identify best performing enzymes for Adisseo's animal nutrition applications. Partnership marked by speed, collaborative approach, and successful milestone achievement.
- BonumosecoreCollaborative enzyme development project resulting in achievement of success milestones. Bonumose impressed with Allozymes' dynamic approach to achieving project goals.
- Harrison SPARCcorePartnership focused on developing next-generation technologies for sustainable specialty chemical manufacturing used in lubricant and construction markets. Marked by open dialogue, scientific rigor, and shared vision for sustainability.
Scale indicators4 records
Recent moves8 records
Expansion highlights5 records
Allozymes competitors and assessment
Company assessmentOthers
- Culture Biosciences: Culture Biosciences operates a cloud-based bioprocess development platform running fermentation experiments for biotech customers. It is adjacent to Allozymes as an enabling services provider in the enzyme and bioprocess development stack, rather than a direct competitor.
- Solugen: Solugen develops bio-based specialty chemicals using engineered enzymes and biomanufacturing processes for industrial markets. It is comparable as an industrial biotech player using biocatalysis to displace traditional chemistry, with overlap to Allozymes' industrial chemicals vertical but as a downstream consumer of enzyme technology.
Emerging players
- Demeetra AgBio: Demeetra AgBio is a gene and enzyme engineering company developing biocatalysts for agriculture, food, and industrial customers. It is comparable as an emerging player in enzyme engineering serving overlapping end-markets, though smaller and earlier-stage than Allozymes.
- Cradle: Cradle (formerly Biomatter) uses generative AI to design novel proteins and enzymes for biotech and industrial customers. It overlaps with Allozymes on ML-guided protein engineering but differs by emphasizing AI-led generative design over high-throughput physical screening.
- EnginZyme: EnginZyme develops engineered enzymes for sustainable chemical manufacturing, including specialty chemicals and pharmaceuticals. It overlaps with Allozymes on biocatalysis for industrial chemistry and shares the positioning of replacing petrochemical processes with enzymatic alternatives.
- Basecamp Research: Basecamp Research is building a proprietary enzyme discovery platform based on genomic data from natural sequences, combined with ML-guided design. It overlaps with Allozymes on data-driven protein engineering but emphasizes novel sequence discovery over high-throughput variant screening of existing scaffolds.
Direct peers
- Codexis: Codexis is a public enzyme engineering company using directed evolution and computational design to develop biocatalysts for pharmaceutical manufacturing and industrial applications. It is the closest direct competitor to Allozymes, having previously acquired Arctus Therapeutics specifically to expand into RNA ligase-driven oligonucleotide manufacturing — the same vertical Allozymes prioritizes.
- Bota Bio: Bota Bio is a synthetic biology company combining enzyme engineering, ML-guided design, and strain development to serve industrial biotech customers across chemicals, food, and pharma. It is comparable to Allozymes in platform-plus-products architecture, horizontal end-market focus, and funding stage.
Broad incumbents
- Ginkgo Bioworks: Ginkgo Bioworks is a large, publicly listed synthetic biology platform offering cell engineering, enzyme engineering, and bioprocess services across many end-markets. It is comparable as a broad synbio incumbent with overlapping enzyme engineering capabilities, but at vastly greater scale and capital intensity.
- Novonesis: Novonesis (formed from the merger of Novozymes and Chr. Hansen) is the world's largest industrial enzyme company, supplying enzymes across food, animal nutrition, and industrial processing. It is comparable as a broad incumbent in the same enzyme end-markets Allozymes targets, with substantially larger resources and customer reach.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Allozymes social profiles
Digital presenceAllozymes financial estimates
Financial estimateRevenue estimate
Valuation estimate
Allozymes leadership team
Management profileNumber of profiles
Profiles9 records
Allozymes funding detail
Funding detailFunding overview
Funding rounds4 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Allozymes M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Allozymes
What does Allozymes do?
Allozymes engineers and supplies high-performance enzymes and enzyme engineering services using its proprietary ZymeLeap platform, which combines ultra-high-throughput microfluidics screening, computational design, and machine learning. The company sells an off-the-shelf portfolio of engineered enzymes (RNA ligases, DNA ligases, glucose dehydrogenases, unspecific peroxygenases, transaminases, amino acid dehydrogenases, adenosine deaminases, and kinases) and offers long-term collaborative enzyme engineering partnerships for pharmaceutical, biotech, industrial chemical, and food/nutrition customers.
Is Allozymes a public or private company?
Allozymes is a private company. It is classified as venture growth investor backed and is currently operating.
When was Allozymes founded?
Allozymes was founded in 2019. It employs 11 to 50 people.
Where is Allozymes based?
Allozymes is headquartered in Singapore, Singapore, in the Asia region.
How does Allozymes make money?
Two revenue lines are on record. Enzyme Product Sales are the primary driver. The others are enzyme Engineering Services.
Who are Allozymes's main competitors?
Others on record are Culture Biosciences and Solugen. Emerging players are Demeetra AgBio, Cradle, EnginZyme and Basecamp Research. Direct peers are Codexis and Bota Bio. Broad incumbents are Ginkgo Bioworks and Novonesis.
Does Allozymes have an API?
No public API is recorded for Allozymes.
What industry is Allozymes in?
Allozymes's product category is Enzyme Engineering and Biocatalysis. Its primary akta.pro industry code is HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization), with a secondary code of EUAAAIAL, Enzymes & Industrial Biotechnology Inputs (Enzymes, Microbial Strains, Fermentation Aids). Its NAICS code is 541714 and its SIC code is 8731.